Fully Synthetic Carbohydrate-based Vaccine Development

Fully Synthetic Carbohydrate-based Vaccine Development

Fully synthetic vaccines, which combine one or more molecular antigens with a synthetic carrier with a well-defined chemical structure, are a new direction in the development of carbohydrate-based vaccines. CD BioGlyco has established a systematic and professional platform to provide service for our clients in the field of vaccine development.

Fully Synthetic Carbohydrate-based Vaccine

Vaccination is a safe and effective strategy to prevent infection caused by pathogens. Currently, in addition to natural carbohydrate-based vaccines and semi-synthetic carbohydrate-based vaccines, the third type of glycoconjugate vaccine, known as fully synthetic carbohydrate-based vaccine, has gradually attracted researchers' attention. This kind of vaccine consists of not only chemically synthesized carbohydrate antigens but also carriers of synthetic peptides. Most cancers and virus vaccines fall into this category.

Molecularly fully defined, fully synthetic carbohydrate-conjugated vaccines are desirable. Synthetic oligosaccharide antigens and synthetic carriers such as glycolipids or synthetic peptides would replace isolated polysaccharides and expressed proteins, respectively. However, no fully synthetic vaccine is currently commercially available. The most promising candidates are still in the preclinical stage. Achievements have been made in recent years in the development of fully synthetic vaccines constructed with Toll-like receptor (TLR) agonists, which can stimulate immune responses, and tumor-associated carbohydrate antigens (TACAs). These di-, tri- or multi-component vaccine candidates have shown attractive immunological properties.

Fig. 1 Fully synthetic carbohydrate-based vaccine using TLR agonist as build-in adjuvant.Fig.1 Fully synthetic carbohydrate-based vaccine using TLR agonist as build-in adjuvant. (Zhou, 2018)

Process of Vaccine Development

To help our clients ultimately design and produce safer and more effective vaccines, we have developed a professional and advanced platform to provide customers with systematic services, including the selection of cell surface glycan targets, the synthesis of oligosaccharides as the basis for glycosite identification, the preparation of glycoconjugates, etc. The overall process of fully synthetic carbohydrate vaccine development is as follows:

Fully Synthetic Carbohydrate-based Vaccine Development


  • Immunotherapy against pathogen diseases and cancer
  • Increasing immunogenicity of carbohydrate-based antigens
  • Development of more accurate and precious vaccination strategies

Advantages of Us

  • World-class experimental platform and professionally trained laboratory staff.
  • High-quality products, manufactured by the optimal solutions.
  • Customer-focused service, our partners are at the core of our daily work.
  • Systematic and extensive one-stop service.

CD BioGlyco has made great strides in researching synthetic technologies to help our customers design and synthesize more robust fully synthetic carbohydrate-based vaccines. If you are interested in our services, please contact us for more information.


  1. Seeberger, P.H. Discovery of semi- and fully-synthetic carbohydrate vaccines against bacterial infections using a medicinal chemistry approach: Focus review. Chemical Reviews. 2021, 121(7):3598-3626.
  2. Zhou, Z.; et al. Recent progress of fully synthetic carbohydrate-based vaccine using TLR agonist as build-in adjuvant. Chinese Chemical Letters. 2018, 29(01):35-42.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.